Patents by Inventor Jamal Carlos Saeh
Jamal Carlos Saeh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160176906Abstract: The present invention relates to compounds of Formula (I): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit Bcl-2 and/or Bcl-XL activities and may be used for the treatment of cancer.Type: ApplicationFiled: December 15, 2015Publication date: June 23, 2016Applicant: AstraZeneca ABInventors: Robert Bruce Diebold, Thomas Woodrow Gero, Paul Grover, Shan Huang, Stephanos Ioannidis, Claude Afona Ogoe, Jamal Carlos Saeh, Jeffrey Gilbert VARNES
-
Patent number: 9248140Abstract: The present invention relates to compounds of Formula (I): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit Bcl-2 and/or Bcl-XL activities and may be used for the treatment of cancer.Type: GrantFiled: February 18, 2015Date of Patent: February 2, 2016Assignee: AstraZeneca ABInventors: Robert Bruce Diebold, Thomas Woodrow Gero, Paul Grover, Shan Huang, Stephanos Ioannidis, Claude Afona Ogoe, Jamal Carlos Saeh
-
Publication number: 20150328239Abstract: The present invention relates to compounds of Formula (I): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit Bcl-2 and/or Bcl-XL activities and may be used for the treatment of cancer.Type: ApplicationFiled: February 18, 2015Publication date: November 19, 2015Applicant: AstraZeneca ABInventors: Robert Bruce Diebold, Thomas Woodrow Gero, Paul Grover, Shan Huang, Stephanos Ioannidis, Claude Afona Ogoe, Jamal Carlos Saeh, Jeffrey Gilbert VARNES
-
Patent number: 9018381Abstract: The present invention relates to compounds of Formula (I): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit Bcl-2 and/or Bcl-XL activities and may be used for the treatment of cancer.Type: GrantFiled: August 5, 2011Date of Patent: April 28, 2015Assignee: AstraZeneca ABInventors: Robert Bruce Diebold, Thomas Gero, Paul Grover, Shan Huang, Stephanos Ioannidis, Claude Afona Ogoe, Jamal Carlos Saeh
-
Publication number: 20130310344Abstract: The present invention relates to compounds of Formula (I): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit Bcl-2 and/or Bcl-XL activities and may be used for the treatment of cancer.Type: ApplicationFiled: August 5, 2011Publication date: November 21, 2013Applicant: ASTRAZENECA ABInventors: Robert Bruce Diebold, Thomas Gero, Paul Grover, Shan Huang, Stephanos Ioannidis, Claude Afona Ogoe, Jamal Carlos Saeh, Jeffrey Gilbert Varnes
-
Patent number: 8461170Abstract: The present invention relates to compounds of Formula (I) and/or Formula (Ia): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit ALK kinase activity, and thus may be used for the treatment of cancer.Type: GrantFiled: August 2, 2011Date of Patent: June 11, 2013Assignee: Astrazeneca ABInventors: Brian Aquila, Victor Kamhi, Bo Peng, Timothy Pontz, Jamal Carlos Saeh, Kumar Thakur, Bin Yang
-
Publication number: 20120035134Abstract: The present invention relates to compounds of Formula (I): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit Bcl-2 and/or Bcl-XL activities and may be used for the treatment of cancer.Type: ApplicationFiled: August 5, 2011Publication date: February 9, 2012Applicant: ASTRAZENECA ABInventors: Robert Bruce DIEBOLD, Thomas GERO, Paul GROVER, Shan HUANG, Stephanos IOANNIDIS, Claude Afona OGOE, Jamal Carlos SAEH, Jeffrey Gilbert VARNES
-
Publication number: 20120028924Abstract: The present invention relates to compounds of Formula (I) and/or Formula (Ia): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit ALK kinase activity, and thus may be used for the treatment of cancer.Type: ApplicationFiled: August 2, 2011Publication date: February 2, 2012Applicant: ASTRAZENECA ABInventors: Brian AQUILA, Victor KAMHI, Bo PENG, Timothy PONTZ, Jamal Carlos SAEH, Kumar THAKUR, Bin YANG
-
Publication number: 20100317593Abstract: Provided herein are 2,3-dihydro-1H-indene compounds, methods for making the compounds, pharmaceutical compositions containing the compounds. The described compounds inhibit IAP proteins and can be used to treat various cancers.Type: ApplicationFiled: June 8, 2010Publication date: December 16, 2010Applicant: ASTRAZENECA ABInventors: Brian Aquila, Edward Hennessy, Alexander Hird, Vibha Oza, Jamal Carlos Saeh, Li Sha
-
Publication number: 20100197749Abstract: The invention relates to chemical compounds of formula (I) and (II): or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.Type: ApplicationFiled: January 15, 2007Publication date: August 5, 2010Applicant: ASTRAZENECA ABInventors: Scott Cowen, Tracey Deegan, Gurmit Grewal, Vibha Oza, Jamal Carlos Saeh, Qibin Su
-
Publication number: 20100029643Abstract: The invention relates to chemical compounds of formula (I), (Ia) and (Ib) or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-cancer effect in a warm-blooded animal, such as man.Type: ApplicationFiled: November 8, 2007Publication date: February 4, 2010Applicant: ASTRAZENECA ABInventors: Gurmit Grewal, Edward Hennessy, Victor Kamhi, Danyang Li, Paul Lyne, Vibha Oza, Jamal Carlos Saeh, Qibin Su, Bin Yang
-
Publication number: 20090111860Abstract: The present invention relates to compounds of formula (I) that mediate Edg, including Edg-1, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant vascularization or inflammatory component such as in tumor-related diseases. The present invention also relates to compounds that inhibit a5bl, and also that exhibit appropriate selectivity profile(s) against other integrins.Type: ApplicationFiled: April 20, 2007Publication date: April 30, 2009Applicant: ASTRAZENECA ABInventors: Gurmit Grewal, Edward Hennessy, Victor Kamhi, Danyang Li, Vibha Oza, Jamal Carlos Saeh, Qibin Su
-
Publication number: 20090105324Abstract: The invention relates to chemical compounds of formula (I): or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.Type: ApplicationFiled: April 20, 2007Publication date: April 23, 2009Applicant: AstraZeneca ABInventors: Gurmit Grewal, Vibha Oza, Jamal Carlos Saeh, Qibin Su